INSTITUTE OF GLOBAL HEALTH INNOVATION

Imperial College London

Mitigating Anti-microbial Resistance by Innovative Solutions in AI (MARISA)

Hutan Ashrafian
Lead for AI and Big Data, IGHI
hutan@ic.ac.uk

INSTITUTE OF GLOBAL HEALTH INNOVATION

Global Risk

Imperial College London



INSTITUTE OF GLOBAL HEALTH INNOVATION

Consensus Priority Settings

Imperial College London

Phase I

- Objective: Gather uncertainties (questions insufficiently addressed by current research)
- Method: Survey World Experts and identify supporting literature

Phase II

- Objective: Develop a short list of uncertainties
- Method: Interim prioritization survey of stakeholders

Phase III

- Objective: Arrive at a top list of research priorities
- Method: Remote/Email prioritisation process

INSTITUTE OF GLOBAL HEALTH INNOVATION

Evidence Gaps and Uncertainties in AMR

Imperial College London

(i)Antibiotic/Drug Design

(ii)Novel/non-classical-drug solutions, eg biologics and other technologies

(iii)Combination solutions

(iv)Biomarker design (population)

(v)POC tests

(vi)Antibiotic/Drug re-purposing

(vii)Precision medicine/individual prediction

(viii)Population prediction/identification of high-risk individuals (genomics/EHR)

(ix)Behavioural modification

(x)AMR Surveillance/epidemic surveillance

(xi)Economic Resource allocation

(xii)Health policy development

(xiii)Big Data Analytics and Real World Evidence

(xiv)Communication of AMR